0000905718-18-000979.txt : 20181219
0000905718-18-000979.hdr.sgml : 20181219
20181219161808
ACCESSION NUMBER: 0000905718-18-000979
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181217
FILED AS OF DATE: 20181219
DATE AS OF CHANGE: 20181219
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: EMSTER KURT VON
CENTRAL INDEX KEY: 0001252524
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36500
FILM NUMBER: 181243658
MAIL ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD
STREET 2: SUITE 350
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CymaBay Therapeutics, Inc.
CENTRAL INDEX KEY: 0001042074
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943103561
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7575 GATEWAY BOULEVARD
STREET 2: SUITE 110
CITY: NEWARK
STATE: CA
ZIP: 94560
BUSINESS PHONE: 510-293-8800
MAIL ADDRESS:
STREET 1: 7575 GATEWAY BOULEVARD
STREET 2: SUITE 110
CITY: NEWARK
STATE: CA
ZIP: 94560
FORMER COMPANY:
FORMER CONFORMED NAME: METABOLEX, INC.
DATE OF NAME CHANGE: 20090721
FORMER COMPANY:
FORMER CONFORMED NAME: METABOLEX INC
DATE OF NAME CHANGE: 19970710
4
1
cymabaytherafm4_dec172018.xml
OWNERSHIP DOCUMENT
X0306
4
2018-12-17
0
0001042074
CymaBay Therapeutics, Inc.
CBAY
0001252524
EMSTER KURT VON
C/O CYMABAY THERAPEUTICS, INC.
7999 GATEWAY BLVD, SUITE 130
NEWARK
CA
94560
1
0
0
0
Common Stock
2018-12-17
4
S
0
88889
8.17
D
184528
I
See footnotes
Common Stock
2018-12-18
4
S
0
53492
7.4285
D
131036
I
See footnotes
Common Stock
18316
I
By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005
Common Stock
90000
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.03 to $8.51 per share, inclusive.
The Reporting Person undertakes to provide to Cymabay Therapeutics, Inc. ("Issuer") any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI.
From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.24 to $8.10 per share, inclusive.
/s/ John Heard, as attorney-in-fact
2018-12-19